Pharmaceutical manufacturers of Sofosbuvir

TAPI stands as the primary global provider of active pharmaceutical ingredients (APIs). With the most extensive range of over 370 high-caliber API products in the industry, we cater to almost 1,000 clients across more than 100 nations. Operating as an independent division under Teva Pharmaceutical Industries, our legacy in the generic API sector spans over 80 years. Situated in close proximity to Tel Aviv, Israel, TAPI boasts a workforce of over 5,000 professionals spread across 19 facilities worldwide. Our cutting-edge manufacturing plants are situated in Italy, Hungary, the Czech Republic, Croatia, Israel, India, China, Mexico, and several other locations.

VIRUPAKSHA ORGANICS LIMITED operates as a fully integrated manufacturer of Active Pharmaceutical Ingredients (API’s) and intermediates in Hyderabad, Telangana, India. The company is overseen by professionals from the pharmaceutical industry with over 25 years of expertise. The successful combination of technical knowledge, organizational capabilities, experience, and infrastructure has contributed to the company's achievements and expansion. Established in 2003, the company achieved an impressive turnover of USD 30 million in its 10th year of operation.

In just over a decade, Laurus has positioned itself as one of the largest and most innovative API producers globally. Expanding upon its established expertise in chemistry, Laurus has recently adopted full vertical integration, including a strong finished dosage capacity, dedicated capacity for backward integration, and also Synthesis R&D operations in India and the USA.

Cambrex stands as a prominent global contract development and manufacturing organization (CDMO) delivering comprehensive analytical and IND enabling services, along with drug substance development and manufacturing throughout the entire drug lifecycle. Boasting 40 years of expertise and a workforce of 2,000 professionals catering to international clients from North America and Europe, Cambrex is a reliable ally in both the branded and generic markets for API development and manufacturing. The company provides a variety of specialized drug substance technologies and capabilities.

Srini Pharmaceuticals Pvt. Ltd., was established in 1995. USFDA, TGA and KFDA approved fully integrated global pharmaceutical company, located just about 60 KM's away from the Pharma Capital of India, Hyderabad. Our manufacturing facility has five fully equipped production blocks with most efficient functional utilities with multiple clean rooms having the ability to produce 10 API's at a time, supported by central quality control laborites with all sophisticated instruments by maintaining complete QMS. The state-of-the-Art Research and development laboratory recognized and approved by Department of Science and Technology, Government of India.

Changzhou Pharmaceutical Factory (CPF) is a subsidiary company of Shanghai Pharma Holdings Co., Ltd., It is headquartered in Changzhou, Jiangsu province, China, Changzhou pharmaceutical Factory has a rich history & Lineage in the pharmaceutical sector. The company was founded in 1949 by (Tan Ruiting) with a registered capital 108 million yuan and the company was restructured as a Changzhou pharmaceutical Factory under the aegis of Shanghai Pharma Group. The Chinese business of Changzhou pharmaceutical factory was full fledged sales & marketing organization,Changzhou Pharma is a one of the prominent players in the Chinese pharmaceutical formulations market with a strong foothold across multiple therapies. The company have more than 1500 employees across the country and has earned a reputation amongest the Chinese pharmaceutical companies for providing innovative, comprehensive and complete healthcare solutions. At Changzhou pharmaceutical Factory, we have one of the strongest global commercial infrastructures in the industry, with a balanced reach across US, Europe, the Asia Pacific region and emerging markets. Our high quality manufacturing dedicated facilities for Oncology, Non Oncology, Complex Generics, OTC-Products and sterile injectables, scientific excellence and vast supply chain network to improve access to medicine for patients worldwide. The company mainly involves leading pharmaceutical manufacturer a wide range of key Intermediates, Active pharmaceutical ingredients, Finished Formulations meet with global standards, Changzhou Pharmaceutical Factory it covers an area of 300,000㎡ including R&D, dedicated manufacturing, international marketing office. And we maintain an industry -leading pipeline, composed of numerous complex generics and state owned brands. The company annually brings 800 tons of API's and 3000 millions of Finished dosage forms across the Globe.

Dong-A has held the position of the largest pharmaceutical company in Korea since 1967. Our predominant market presence is attributed to internally developed products such as Suganon tab, Evogliptin, which is a DPP-4 inhibitor for type 2 diabetes mellitus, Zydena tab, which is Udenafil, the fourth PDE5 inhibitor globally for erectile dysfunction, Stillen tab, a herbal treatment for gastritis with Eupatilin, and Motilitone tab, which contains Corydaline for functional dyspepsia. Additionally, we provide branded generic drugs (anti-cancer, anti-TB, etc.), bio-pharmaceutical, IMD, APIs, and OTC products.

ST Pharm has provided exceptional custom production services for oligonucleotides and small molecule APIs CDMO to fulfill clients’ elevated requirements in pharmaceutical development while adhering to cGMP regulations. The enhancement of oligonucleotide manufacturing capabilities has emerged as a new driving force for the future of the pharmaceutical industry

As a new characteristic API and CDMO pharmaceutical enterprises specializing in the development, production and sales of modern medicines, Jiangsu Yutian Pharmaceutical Co., Ltd. is committed to providing high-quality APIs and Intermediates to major pharmaceutical companies in China, and our products are also well sold in Europe, Japan, South Korea, India and other dozens of countries. Now, we are one of the key national high-tech enterprises of China, a small science and technology giant enterprise of the city, and a backbone enterprise of the new pharmaceutical industry base of China Pharmaceutical Port.

Established in 2005, Coben Group was created and constructed in accordance with GMP standard covering a total area of 100,000 square meters. It is a part of ZJMI Group-Global Fortune 500, achieving the 270th position in 2018. Coben specializes in the research and production of APIs and intermediates for a variety of medications. Its primary products consist of Sofosbuvir, Tenofovir, Ticagrelor, Sacubitril, Voriconazole, Isavuconazole, and their respective intermediates.